Published in Clin Pharmacol Ther on April 07, 2010
Genetics Informatics Trial (GIFT) of Warfarin to Prevent DVT (GIFT) | NCT01006733
A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med (2013) 7.09
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther (2011) 4.42
A new warfarin dosing algorithm including VKORC1 3730 G > A polymorphism: comparison with results obtained by other published algorithms. Eur J Clin Pharmacol (2012) 2.07
Pharmacogenetics in the evaluation of new drugs: a multiregional regulatory perspective. Nat Rev Drug Discov (2013) 1.78
Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial. Trials (2010) 1.72
Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. Annu Rev Pharmacol Toxicol (2014) 1.58
Warfarin pharmacogenetics. Trends Cardiovasc Med (2014) 1.57
Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy. Thromb Haemost (2011) 1.35
The future of warfarin pharmacogenetics in under-represented minority groups. Future Cardiol (2012) 1.25
Role of pharmacogenomics in the management of traditional and novel oral anticoagulants. Pharmacotherapy (2011) 1.16
Rationale and design of the Clarification of Optimal Anticoagulation through Genetics trial. Am Heart J (2013) 1.12
Feasibility of implementing a comprehensive warfarin pharmacogenetics service. Pharmacotherapy (2013) 1.09
Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon. Br J Clin Pharmacol (2014) 0.97
Race influences warfarin dose changes associated with genetic factors. Blood (2015) 0.96
Warfarin dose prediction in children using pharmacometric bridging--comparison with published pharmacogenetic dosing algorithms. Eur J Clin Pharmacol (2013) 0.91
Clinical and genetic determinants of warfarin pharmacokinetics and pharmacodynamics during treatment initiation. PLoS One (2011) 0.90
Pharmacogenomics: application to the management of cardiovascular disease. Clin Pharmacol Ther (2011) 0.89
A pharmacogenetics-based warfarin maintenance dosing algorithm from Northern Chinese patients. PLoS One (2014) 0.87
Genetics-based pediatric warfarin dosage regimen derived using pharmacometric bridging. J Pediatr Pharmacol Ther (2013) 0.87
Warfarin anticoagulant therapy: a Southern Italy pharmacogenetics-based dosing model. PLoS One (2013) 0.87
Comparison of delivery strategies for pharmacogenetic testing services. Pharmacogenet Genomics (2014) 0.87
Testing of VKORC1 and CYP2C9 alleles to guide warfarin dosing. Test category: pharmacogenomic (treatment). PLoS Curr (2010) 0.84
Pharmacogenetics of anticoagulants. Hum Genomics Proteomics (2010) 0.84
Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation. Pharmacogenomics (2012) 0.83
An acenocoumarol dosing algorithm using clinical and pharmacogenetic data in Spanish patients with thromboembolic disease. PLoS One (2012) 0.82
Copy number variation and warfarin dosing: evaluation of CYP2C9, VKORC1, CYP4F2, GGCX and CALU. Pharmacogenomics (2011) 0.81
Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin. Semin Thromb Hemost (2012) 0.81
Pharmacogenetics-Based versus Conventional Dosing of Warfarin: A Meta-Analysis of Randomized Controlled Trials. PLoS One (2015) 0.81
Development of a pharmacogenetic-guided warfarin dosing algorithm for Puerto Rican patients. Pharmacogenomics (2012) 0.79
A multi-factorial analysis of response to warfarin in a UK prospective cohort. Genome Med (2016) 0.78
A Novel Admixture-Based Pharmacogenetic Approach to Refine Warfarin Dosing in Caribbean Hispanics. PLoS One (2016) 0.78
A new nested allele-specific multiplex polymerase chain reaction method for haplotyping of VKORC1 gene to predict warfarin sensitivity. Biomed Res Int (2014) 0.78
Meta-analysis of Randomized Controlled Trials of Genotype-Guided vs Standard Dosing of Warfarin. Chest (2015) 0.78
Improved accuracy of anticoagulant dose prediction using a pharmacogenetic and artificial neural network-based method. Eur J Clin Pharmacol (2013) 0.77
Warfarin Dosing Algorithms and the Need for Human Intervention. Am J Med (2015) 0.77
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther (2017) 0.76
Warfarin dose requirement in Turkish patients: the influences of patient characteristics and polymorphisms in CYP2C9, VKORC1 and factor VII. Hippokratia (2015) 0.76
Protein engineering: a new frontier for biological therapeutics. Curr Drug Metab (2014) 0.76
Personalized medicine in rheumatoid arthritis: miles to go before we sleep. Arthritis Rheum (2011) 0.76
Genetic determinants of variability in warfarin response after the dose-titration phase. Pharmacogenet Genomics (2016) 0.76
Pharmacogenetic association study of warfarin safety endpoints in Puerto Ricans. P R Health Sci J (2014) 0.76
Genome-wide association study of warfarin maintenance dose in a Brazilian sample. Pharmacogenomics (2015) 0.76
Iterative Development and Evaluation of a Pharmacogenomic-Guided Clinical Decision Support System for Warfarin Dosing. Appl Clin Inform (2016) 0.75
The Impact of Inpatient Versus Outpatient Initiation on Early Warfarin Dosing. Am J Cardiovasc Drugs (2015) 0.75
A Proposal for an Individualized Pharmacogenetic-Guided Warfarin Dosage Regimen for Puerto Rican Patients Commencing Anticoagulation Therapy. J Pharmacogenomics Pharmacoproteomics (2014) 0.75
Anticoagulation endpoints with clinical implementation of warfarin pharmacogenetic dosing in a real-world setting: A proposal for a new pharmacogenetic dosing approach. Clin Pharmacol Ther (2016) 0.75
Cost-effectiveness of pharmacogenetic-guided dosing of warfarin in the United Kingdom and Sweden. Pharmacogenomics J (2016) 0.75
Clinical Pharmacogenetic Testing and Application: Laboratory Medicine Clinical Practice Guidelines. Ann Lab Med (2017) 0.75
Gene-drug interaction in stroke. Stroke Res Treat (2011) 0.75
Warfarin pharmacogenetics: does more accurate dosing benefit patients? Semin Thromb Hemost (2012) 0.75
Pharmacogenomics of hypertension and heart disease. Curr Hypertens Rep (2015) 0.75
A New Pharmacogenetic Algorithm to Predict the Most Appropriate Dosage of Acenocoumarol for Stable Anticoagulation in a Mixed Spanish Population. PLoS One (2016) 0.75
Pharmacogenetics in Jewish populations. Drug Metabol Drug Interact (2014) 0.75
Influence of the CYP4F2 polymorphism on the risk of hemorrhagic complications in coumarin-treated patients. Saudi Med J (2016) 0.75
A systematic analysis and comparison of warfarin initiation strategies. Pharmacogenet Genomics (2016) 0.75
Effects of VKORC1 Genetic Polymorphisms on Warfarin Maintenance Dose Requirement in a Chinese Han Population. Med Sci Monit (2015) 0.75
CYP2C19*17 affects R-warfarin plasma clearance and warfarin INR/dose ratio in patients on stable warfarin maintenance therapy. Eur J Clin Pharmacol (2015) 0.75
A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition (1992) 16.89
Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med (2009) 12.63
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med (2005) 8.77
Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. A randomized, double-blind, controlled trial. Ann Intern Med (2003) 8.33
Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 7.94
National surveillance of emergency department visits for outpatient adverse drug events. JAMA (2006) 6.24
Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation (2007) 5.99
Systematic overview of warfarin and its drug and food interactions. Arch Intern Med (2005) 5.86
Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med (2007) 5.29
Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA (2002) 5.26
The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood (2005) 4.91
A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood (2004) 4.70
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther (2008) 4.54
Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med (1997) 4.47
CYP4F2 genetic variant alters required warfarin dose. Blood (2008) 4.23
Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J (2005) 3.75
Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med (2009) 3.44
Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin Pharmacol Ther (2006) 3.06
A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet (2005) 2.97
The largest prospective warfarin-treated cohort supports genetic forecasting. Blood (2008) 2.79
Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost (2004) 2.64
Initiation of warfarin therapy in elderly medical inpatients: a safe and accurate regimen. Am J Med (2005) 2.63
Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol Ther (2007) 2.54
Incidence of fatal adverse drug reactions: a population based study. Br J Clin Pharmacol (2007) 2.29
Heparin-induced increase in the international normalized ratio. Responses of 10 commercial thromboplastin reagents. Am J Clin Pathol (1995) 2.29
Genetic-based dosing in orthopedic patients beginning warfarin therapy. Blood (2007) 2.23
Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood (2008) 2.18
Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med (2008) 2.05
The influence of sequence variations in factor VII, gamma-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement. Thromb Haemost (2006) 2.04
Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy. Blood (2008) 1.99
Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans. Clin Pharmacol Ther (2008) 1.90
Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study. J Thromb Thrombolysis (2006) 1.78
Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype. Pharmacogenetics (2004) 1.75
A randomized trial comparing 5-mg and 10-mg warfarin loading doses. Arch Intern Med (1999) 1.72
Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost (2000) 1.67
VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. Pharmacogenomics (2008) 1.65
Use of genetic and nongenetic factors in warfarin dosing algorithms. Pharmacogenomics (2007) 1.53
Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients. J Thromb Haemost (2008) 1.51
Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. Pharmacogenomics J (2004) 1.51
A rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding. Genet Med (2008) 1.50
Increased sensitivity to warfarin after heart valve replacement. Ann Pharmacother (2006) 1.50
Warfarin: almost 60 years old and still causing problems. Br J Clin Pharmacol (2006) 1.50
Exaggerated initial response to warfarin following heart valve replacement. Am J Cardiol (1999) 1.47
Genetic testing for warfarin dosing? Not yet ready for prime time. Pharmacotherapy (2008) 1.35
Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study. Pharmacogenet Genomics (2009) 1.09
Incidence and predictors of severe bleeding during warfarin treatment. J Thromb Thrombolysis (2007) 1.09
Effects of CYP4F2 genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy. Pharmacogenet Genomics (2009) 1.06
Effect of CYP2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement. Pharmacogenet Genomics (2009) 0.96
Factors affecting warfarin therapy following cardiac valve surgery. Ann Pharmacother (2002) 0.86
Five-day food intake in elderly female outpatients with Parkinson's disease, rheumatoid arthritis or stroke. J Nutr Health Aging (2004) 0.79
Initial sequencing and analysis of the human genome. Nature (2001) 212.86
Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci U S A (1990) 16.34
A gene map of the human genome. Science (1996) 14.32
Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). Proc Natl Acad Sci U S A (1996) 12.89
Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med (2009) 12.63
Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet (2007) 12.62
Socioeconomic factors, health behaviors, and mortality: results from a nationally representative prospective study of US adults. JAMA (1998) 11.90
15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell (1995) 11.72
Highly parallel SNP genotyping. Cold Spring Harb Symp Quant Biol (2003) 9.10
Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med (2000) 8.68
An early haematopoietic defect in mice lacking the transcription factor GATA-2. Nature (1994) 8.60
Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell (1997) 8.28
Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children. BMJ (2000) 8.10
Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci U S A (1997) 7.52
Histone H2AX is phosphorylated in an ATR-dependent manner in response to replicational stress. J Biol Chem (2001) 7.35
Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study. Lancet (2008) 7.05
Control of p70 s6 kinase by kinase activity of FRAP in vivo. Nature (1995) 7.05
Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment. Immunity (1995) 6.91
Phosphatidic acid-mediated mitogenic activation of mTOR signaling. Science (2001) 6.47
Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci U S A (1980) 6.31
Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. Nat Med (1997) 6.13
Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science (1996) 5.92
Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. Cell (1997) 5.92
The transcription factor associated Ccr4 and Caf1 proteins are components of the major cytoplasmic mRNA deadenylase in Saccharomyces cerevisiae. Cell (2001) 5.86
Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev (1994) 5.68
Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther (2011) 5.44
Genetic diversity and disease control in rice. Nature (2000) 5.34
An essential role for Rac in Ras transformation. Nature (1995) 5.34
Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med (1994) 5.12
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol (2009) 5.08
Comparison of human genetic and sequence-based physical maps. Nature (2001) 4.97
The periodic association of MAP2 with brain microtubules in vitro. J Cell Biol (1979) 4.97
Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell (1999) 4.76
Non-Hodgkin's lymphomas. IV. Clinicopathologic correlation in 405 cases. Cancer (1973) 4.66
Homeostasis-stimulated proliferation drives naive T cells to differentiate directly into memory T cells. J Exp Med (2000) 4.54
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther (2008) 4.54
Human marrow stromal cell therapy for stroke in rat: neurotrophins and functional recovery. Neurology (2002) 4.45
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther (2011) 4.42
Conduction slowing and sudden arrhythmic death in mice with cardiac-restricted inactivation of connexin43. Circ Res (2001) 4.38
Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J Clin Invest (1997) 4.31
Phylogenetic affiliation of the pseudomonads based on 16S rRNA sequence. Int J Syst Evol Microbiol (2000) 4.31
Expression of the transcription factor deltaFosB in the brain controls sensitivity to cocaine. Nature (1999) 4.29
Demethylation-induced developmental pleiotropy in Arabidopsis. Science (1996) 4.25
Overland heroin trafficking routes and HIV-1 spread in south and south-east Asia. AIDS (2000) 4.24
A revised classification of Vibrio fetus. Am J Vet Res (1971) 4.15
MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell (1996) 4.13
Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide dismutase. Arch Biochem Biophys (1992) 4.12
Fringe is a glycosyltransferase that modifies Notch. Nature (2000) 4.09
Extensive nitration of protein tyrosines in human atherosclerosis detected by immunohistochemistry. Biol Chem Hoppe Seyler (1994) 4.09
Crystal structure of the cytochrome bc1 complex from bovine heart mitochondria. Science (1997) 4.07
A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci U S A (2000) 4.06
Effect of mobile phone intervention for diabetes on glycaemic control: a meta-analysis. Diabet Med (2011) 4.04
Tumor suppressor p53 binding protein 1 (53BP1) is involved in DNA damage-signaling pathways. J Cell Biol (2001) 3.92
Identification of a nuclear receptor that is activated by farnesol metabolites. Cell (1995) 3.92
Histochemical and ultrastructural demonstration of gamma-glutamyl transpeptidase activity. J Histochem Cytochem (1969) 3.91
B-1 and B-2 cell-derived immunoglobulin M antibodies are nonredundant components of the protective response to influenza virus infection. J Exp Med (2000) 3.89
Exaggerated neuroinflammation and sickness behavior in aged mice following activation of the peripheral innate immune system. FASEB J (2005) 3.84
Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes (2001) 3.83
Genetic analysis of BRCA1 function in a defined tumor cell line. Mol Cell (1999) 3.83
Two regulatory genes of the maize anthocyanin pathway are homologous: isolation of B utilizing R genomic sequences. Plant Cell (1989) 3.83
Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell (1999) 3.76
Submucosal endoscopic esophageal myotomy: a novel experimental approach for the treatment of achalasia. Endoscopy (2007) 3.75
Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J (2005) 3.75
Pooled exposure-response analyses and risk assessment for lung cancer in 10 cohorts of silica-exposed workers: an IARC multicentre study. Cancer Causes Control (2001) 3.74
Unique response pathways are established by allosteric interactions among nuclear hormone receptors. Cell (1995) 3.70
Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene (2009) 3.64
A role for Rho in Ras transformation. Proc Natl Acad Sci U S A (1995) 3.59
TOPAS: an innovative proton Monte Carlo platform for research and clinical applications. Med Phys (2012) 3.57
Which drugs cause preventable admissions to hospital? A systematic review. Br J Clin Pharmacol (2006) 3.56
TOR kinase domains are required for two distinct functions, only one of which is inhibited by rapamycin. Cell (1995) 3.56
Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther (2011) 3.53
Directional guidance of neuronal migration in the olfactory system by the protein Slit. Nature (1999) 3.51
The knockout of miR-143 and -145 alters smooth muscle cell maintenance and vascular homeostasis in mice: correlates with human disease. Cell Death Differ (2009) 3.43
Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature (1995) 3.39
Enhancement of blue-light sensitivity of Arabidopsis seedlings by a blue light receptor cryptochrome 2. Proc Natl Acad Sci U S A (1998) 3.34
A critical role of natural immunoglobulin M in immediate defense against systemic bacterial infection. J Exp Med (1998) 3.32
p62, a phosphotyrosine-independent ligand of the SH2 domain of p56lck, belongs to a new class of ubiquitin-binding proteins. J Biol Chem (1996) 3.27
Attenuation of isoproterenol-mediated vasodilatation in blacks. N Engl J Med (1995) 3.25
Pulsed-field fingerprinting of listeriae: identification of genomic divisions for Listeria monocytogenes and their correlation with serovar. Appl Environ Microbiol (1994) 3.24
Androstane metabolites bind to and deactivate the nuclear receptor CAR-beta. Nature (1998) 3.23
The full-length leptin receptor has signaling capabilities of interleukin 6-type cytokine receptors. Proc Natl Acad Sci U S A (1996) 3.21
Effects of chronic exposure to cocaine are regulated by the neuronal protein Cdk5. Nature (2001) 3.09
Assessment of gastric emptying using a low fat meal: establishment of international control values. Am J Gastroenterol (2000) 3.08
Oxidative chemistry of peroxynitrite. Methods Enzymol (1994) 3.03
Prevalence of diabetes and impaired fasting glucose in the Chinese adult population: International Collaborative Study of Cardiovascular Disease in Asia (InterASIA). Diabetologia (2003) 3.00
Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res (1994) 2.98
Stable microreentrant sources as a mechanism of atrial fibrillation in the isolated sheep heart. Circulation (2000) 2.97
Longitudinal and cross-sectional analysis of atrophy in pharmacoresistant temporal lobe epilepsy. Neurology (2009) 2.95
Clinical use of the total artificial heart. N Engl J Med (1984) 2.94